Management of atrial fibrillation in patients taking targeted cancer therapies

Aarti Asnani,
Anastasia Manning,
Moussa Mansour,
Jeremy Ruskin,
Ephraim P. Hochberg and
Leon M. PtaszekEmail author

Cardio-Oncology20173:2

https://doi.org/10.1186/s40959-017-0021-y

Received: 9 November 2016
Accepted: 18 January 2017
Published: 9 March 2017

Abstract

Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, several drug-drug interactions have emerged that complicate the use of antiarrhythmic drugs (AADs) in patients with active malignancy. Moreover, specific targeted therapies such as ibrutinib may contribute directly to the development of AF. The decision to pursue systemic anticoagulation can be challenging in patients with malignancy due to a number of factors, including the need for frequent procedures, the presence of malignancy-related risk factors for bleeding, and limited data regarding the safety of the novel oral anticoagulants (NOACs) in cancer patients. This review describes the challenges associated with AF management in patients with cancer and highlights a number of important drug-drug interactions that can impact patient management.